New transplant prep aims to stop blood Cancer's return
NCT ID NCT07183878
Summary
This study is testing if adding a drug called venetoclax to the standard chemotherapy given before a stem cell transplant can help patients with high-risk forms of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to kill more cancer cells before the transplant, which may help prevent the disease from coming back and improve long-term survival. Patients aged 12 to 60 will be randomly assigned to receive either the new combination or the standard preparation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.